Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriem Boufraqech

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Endocrine|July 31, 2015
New genomic somatic amplifications and deletions in papillary thyroid cancerMyriem Boufraqech, Electron Kebebew
Cancers|December 15, 2019
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient OutcomeMyriem Boufraqech, Naris Nilubol
Endocrine|November 10, 2012
TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?Myriem Boufraqech, Catsim Fassassi, Electron Kebebew
Frontiers in Endocrinology|June 13, 2020
New Therapies for Advanced Thyroid CancerDiprajan Laha, Naris Nilubol, Myriem Boufraqech
Best Practice & Research. Clinical Endocrinology & Metabolism|December 8, 2016
MicroRNAs in the thyroidMyriem Boufraqech, Joanna Klubo-Gwiezdzinska, Electron Kebebew
Expert Opinion on Medical Diagnostics|May 25, 2013
Diagnosis of thyroid cancer: state of artMyriem Boufraqech, Dhaval Patel, Yin Xiong, et al.
The Journal of Clinical Endocrinology and Metabolism|March 25, 2014
Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive diseaseNaris Nilubol, Myriem Boufraqech, Lisa Zhang, et al.
Oncotarget|March 3, 2016
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancerLisa Zhang, Myriem Boufraqech, Ross Lake, et al.
Endocrine-Related Cancer|May 15, 2015
Carfilzomib is an effective anticancer agent in anaplastic thyroid cancerAmit Mehta, Lisa Zhang, Myriem Boufraqech, et al.
Oncotarget|June 15, 2016
LOX is a novel mitotic spindle-associated protein essential for mitosisMyriem Boufraqech, Darmood Wei, Urbain Weyemi, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Endocrine|July 31, 2015
New genomic somatic amplifications and deletions in papillary thyroid cancerMyriem Boufraqech, Electron Kebebew
Cancers|December 15, 2019
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient OutcomeMyriem Boufraqech, Naris Nilubol
Endocrine|November 10, 2012
TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?Myriem Boufraqech, Catsim Fassassi, Electron Kebebew
Frontiers in Endocrinology|June 13, 2020
New Therapies for Advanced Thyroid CancerDiprajan Laha, Naris Nilubol, Myriem Boufraqech
Best Practice & Research. Clinical Endocrinology & Metabolism|December 8, 2016
MicroRNAs in the thyroidMyriem Boufraqech, Joanna Klubo-Gwiezdzinska, Electron Kebebew
Expert Opinion on Medical Diagnostics|May 25, 2013
Diagnosis of thyroid cancer: state of artMyriem Boufraqech, Dhaval Patel, Yin Xiong, et al.
The Journal of Clinical Endocrinology and Metabolism|March 25, 2014
Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive diseaseNaris Nilubol, Myriem Boufraqech, Lisa Zhang, et al.
Oncotarget|March 3, 2016
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancerLisa Zhang, Myriem Boufraqech, Ross Lake, et al.
Endocrine-Related Cancer|May 15, 2015
Carfilzomib is an effective anticancer agent in anaplastic thyroid cancerAmit Mehta, Lisa Zhang, Myriem Boufraqech, et al.
Oncotarget|June 15, 2016
LOX is a novel mitotic spindle-associated protein essential for mitosisMyriem Boufraqech, Darmood Wei, Urbain Weyemi, et al.
Pageof 5